Bioepis – Talk Bio

Actionable Insights Powered by AI

Johnson & Johnson Sues Samsung Bioepis Over Alleged Stelara Biosimilar Contract Breach

2 months ago talkbio0Tagged Bioepis, Biosimilars, Contract agreement, Johnson and Johnson, Pyzchiva, Samsung, Stelara, ustekinumab

Johnson & Johnson, Samsung Bioepis, Stelara, biosimilar, lawsuit, contract breach, ustekinumab, Pyzchiva

Samsung Bioepis Sees 107% Sales Growth in Q2, Driven by Biosimilars

9 months ago talkbio0Tagged Bioepis, Biosimilars, Growth, Market, operating profit, Sales - occupational activity, Samsung

Samsung Bioepis, biosimilars, sales growth, Q2, operating profit, market share

Italian Antitrust Agency Investigates Novartis, Biogen, and Others Over Lucentis Biosimilar

11 months ago talkbio0Tagged Antitrust Probe, Authority, Bioepis, Biogen, Biosimilars, Byooviz, competition, genentech, Italian language, Lucentis, Novartis, Samsung

Italian Competition Authority, Novartis, Biogen, Samsung Bioepis, Genentech, Lucentis, Byooviz, Biosimilar, Antitrust Probe